Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + doxorubicin hydrochloride liposome + bevacizumab
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Carboplatin + doxorubicin hydrochloride liposome + bevacizumab is a combination chemotherapy and immunotherapy regimen used in the treatment of platinum-sensitive recurrent ovarian cancer (PSOC). This multi-drug regimen consists of carboplatin (a platinum-based alkylating agent), pegylated liposomal doxorubicin hydrochloride (an anthracycline topoisomerase II inhibitor), and bevacizumab (a humanized monoclonal antibody targeting VEGF-A). In clinical trials, such as the Phase III study NCT07821606 sponsored by Hansoh BioMedical R&D Company, this combination serves as an investigator's choice standard-of-care comparator arm against novel therapies like HS-20089 (mocertatug rezetecan) plus bevacizumab.
- Other names
- carboplatin + doxorubicin liposomal + bevacizumabcarboplatin + pegylated liposomal doxorubicin + bevacizumabcarboplatin + pegylated liposomal doxorubicin hydrochloride + bevacizumabcarboplatin + PLD + bevacizumab
02
Targets
DNATOP2A (DNA topoisomerase II)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on carboplatin + doxorubicin hydrochloride liposome + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + doxorubicin hydrochloride liposome + bevacizumab.